Navigation Links
Blockbuster Expectations Don't Always Translate to Market Reality
Date:4/9/2013

LONDON and BOSTON, April 9, 2013 /PRNewswire/ --

EP Vantage Analyzes Accuracy of Analyst Sales Estimates for Blockbuster and Near-Blockbuster Launches

Pharma industry observers widely expect Biogen Idec's new multiple sclerosis therapy Tecfidera to reach mega-blockbuster status. However, EP Vantage®, EvaluatePharma®'s award-winning editorial team cautions that forecasting revenue for an unlaunched drug isn't always easy. A five-year review of EvaluatePharma's consensus forecasts of analyst predictions for blockbuster or near-blockbuster drug launches found that new products with the biggest hopes often disappoint, while others have vastly outperformed low expectations.

The report, "The Industry's Brightest Hopes: Where Are They Now?" uncovers some remarkable misses prompted by a sea change in treatment, reimbursement issues, safety concerns and heightened competition. While analysts' forecasts don't always ring true on performance, EP Vantage found that forecasts have also been spot on and in some cases performances even exceeded initial estimates.

"Evaluating the accuracy of consensus forecasts is particularly pertinent given the recent US approval of Tecfidera, with consensus data suggesting that this drug's sales could reach $3.7 billion within five years. Many factors can influence the success of a drug and while forecasts have been proven to ring true in many cases, our analysis shows just how far off they can be," commented Jacob Plieth , author of the EP Vantage report.

As the first company to provi
'/>"/>

SOURCE EP Vantage
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
2. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
3. Area Radiology Groups Brand Makeover Redefines Customer Experience Expectations in Healthcare
4. Fluke Biomedical launches six translated websites
5. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Ophthalmic Drugs: World Market Prospects 2012-2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 PharmaEngine, Inc. (TWO:4162) today ... (NASDAQ: MACK ) with its sublicensing partner, ... announced that Baxter has submitted a marketing authorization ... for MM-398 (irinotecan liposome injection), also known as ... pancreas who have been previously treated with gemcitabine-based ...
(Date:5/4/2015)...  Oncobiologics, Inc., a biotherapeutics company focused on ... completed the construction of its GMP commercial launch ... Cranbury, New Jersey . The ... to utilize multiple technologies that enable rapid deployment ... use of the latest single-use technologies, the facility ...
(Date:5/4/2015)... HeartWare International, Inc . (NASDAQ: HTWR ), a leading ... revolutionizing the treatment of advanced heart failure, today announced that ... present at the Bank of America Merrill Lynch 2015 Health ... Thursday, May 14, 2015, at 10:00 a.m. PT (1:00 p.m. ... at the conference will be available via a link on ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... a dynamic, service-oriented healthcare technology company has announced an ... and Practice Management software products. This update will enable ... the requirements set forth by the Centers for Medicare ... (Logo: http://photos.prnewswire.com/prnh/20101115/NY01712LOGO ) Currently, SequelMed ...
... capital, a burdensome and uncertain regulatory environment and lack ... the biggest threats to the biomedical industry,s growth over ... surveyed by CHI-California Healthcare Institute, BayBio and PwC US. ... quarters (74 percent) of biomedical industry CEOs surveyed said ...
Cached Medicine Technology:SequelMed Announces ANSI 5010 Upgrade for Its Users 2Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 2Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 3Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 4Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 5
(Date:5/4/2015)... 04, 2015 The U.S. healthcare worker ... join the ranks of senior citizens (1) and 27 ... already over-burdened healthcare system. Additionally, as older healthcare employees ... them. Per the U.S. Census Bureau, the number of ... 75% by 2050 while those 25 to 54 will ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 ... is now offering a more comfortable and attractive alternative ... restoration of choice for those who have lost teeth. ... can feel insecure or slip at the worst possible ... eats or talks. They can also painfully pinch or ...
(Date:5/4/2015)... 2015 Pricing Healthcare announces it ... one patient receiving care at St. George Surgical Center ... must be performed by July 15th, 2015, and the patient ... up front and forego the filing of insurance claims). , ... every year, and it devastates more and more individuals and ...
(Date:5/4/2015)... Unlike some camps, the Nike Middle School Running ... goal is to educate first and train second, with a significant ... the young runners are building the knowledge base needed to have ... topics covered include Effort Based Training, Running Heroes, Running Vocabulary, and ... This is not a camp where kids come to run ...
(Date:5/4/2015)... Gettysburg, Pennsylvania (PRWEB) May 04, 2015 ... bicycle and hand cycle ride in the last decade ... after riding 110 miles in two days from the ... national non-profit saw 581 registered disabled and able-bodied participants ... Face of America recognizes and honors the commitment and ...
Breaking Medicine News(10 mins):Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4
... new class of drugs based on a widely used ... the laboratory and in mice, according to researchers. The ... treatment of these tumors. // ,Previous drugs ... same cell targets as hydroxyurea, but had serious side ...
... mantra of the media as dozens of people exposed to ... potent antibiotic. But if the supply dwindles, doctors say other ... previous generation's wonder drug: penicillin. Although alternatives exist, Cipro is ... , // ,It helped that Cipro was the ...
... An experimental anti-cancer drug has shown effectiveness in treating ... report. Researchers say the drug probably acts on many ... for treating other types of cancer. Dr. Antonio Fojo ... colleagues tested the drug, depsipeptide//, in patients with T-cell ...
... virus that kills at least 30 percent of its ... the globe more than two decades ago. Scientists retained ... and stored them in secure laboratories in Atlanta, Georgia, ... of many potential bioterrorism threats, but "perhaps it is ...
... warned doctors that doxycycline -- an antibiotic being prescribed ... -- can stunt fetal growth when taken by pregnant ... urged doctors to prescribe Cipro to pregnant women. The ... being overprescribed in the general population, possibly causing common ...
... drugs, statements about drug benefits are often overblown ... expected benefit; instead, they make an emotional appeal," ... New Hampshire. // ,Instead of telling ... medicine is going to prevent some outcome, these ...
Cached Medicine News:
Adult size. Clear plastic. Accommodates either eye. Packaged 12 per box. Available in either adult or pediatric size....
... Flow rate: 45 ... micron. For filtering fluids ... in table; bi-directional membrane ... kg/cm2 (75 psi) via ...
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
20 mm. Plastic, methylmethacrylate. Supplied sterile....
Medicine Products: